Growth Hormone Secretagogue Research Protocol

Growth hormone secretagogues fall into two mechanistic classes that work synergistically. GHRH analogs (Sermorelin, Tesamorelin, CJC-1295) bind the GHRH receptor on pituitary somatotrophs to stimulate GH synthesis and release — they amplify the natural GH pulse. GHRPs/Ghrelin mimetics (Ipamorelin, GHRP-2, GHRP-6, Hexarelin) bind the ghrelin/GHS receptor to initiate GH release and suppress somatostatin (the GH-inhibiting hormone). Combining a GHRH analog with a GHRP produces synergistic GH release — the CJC-1295/Ipamorelin blend leverages this synergy in a single product.

Before initiating a GH secretagogue protocol, obtain baseline laboratory values. Essential: IGF-1 (insulin-like growth factor 1 — the primary biomarker for GH status, reflecting integrated GH exposure over weeks). Recommended: fasting glucose, fasting insulin, HbA1c (GH affects glucose metabolism), lipid panel, and thyroid function (TSH, free T4 — GH can affect thyroid hormone conversion). These baseline values are necessary for meaningful before/after comparison.

Choose a protocol based on your research objective. Option A (simplest): Ipamorelin alone at 200-300 mcg subcutaneously, 2-3 times daily. Option B (GHRH analog): Sermorelin 200-300 mcg or Tesamorelin 1-2 mg subcutaneously, once daily at bedtime. Option C (synergistic combination): CJC-1295/Ipamorelin blend per manufacturer dosing, or separate compounds dosed together. Option D (maximum pulsatility): GHRH analog + GHRP administered together 2-3 times daily at strategic times.

GH secretagogue timing should align with the body's natural GH pulsatile pattern. Key dosing windows: (1) Bedtime — 30 minutes before sleep, aligning with the largest natural GH pulse that occurs during deep sleep. (2) Morning fasted — upon waking, before eating, to leverage the overnight fasting state. (3) Post-exercise — 15-30 minutes after training, when natural GH secretion is elevated. For multi-dose protocols, use 2-3 of these windows. Avoid dosing with food — elevated blood glucose and insulin suppress GH release via somatostatin.

Follow the Subcutaneous Injection Technique Protocol. Standard site is abdominal subcutaneous tissue. For combination protocols (GHRH + GHRP), both peptides can be drawn into the same syringe if the manufacturer confirms compatibility, or administered in separate syringes at injection sites 2 inches apart. Inject slowly and record the time, dose, and site.

Common GH secretagogue effects to monitor: water retention (puffy hands, face — usually transient in the first 2-4 weeks), increased appetite (especially with GHRP-6 due to ghrelin receptor agonism — less so with Ipamorelin), joint stiffness (from fluid retention), tingling or numbness in extremities (carpal tunnel-like symptoms from increased GH), and vivid dreams (particularly with bedtime dosing). These are generally dose-dependent and reversible.

After 6-8 weeks on the protocol, repeat the baseline blood panel. Compare IGF-1 levels against baseline — a meaningful increase (typically 20-50% above baseline) confirms the secretagogue is stimulating GH release. Review glucose and insulin markers for any adverse metabolic shifts. Reassess the protocol: adjust dose, timing, or compound selection based on results. Plan cycling: 8-12 weeks on, 4-6 weeks off is a common framework to prevent receptor desensitization.